Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Acer save search
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Published: 2022-12-27 (Crawled : 14:00) - globenewswire.com
RLFTF | $1.45 11.45% 2.2K
|
n/a
|
| O: 3.33%
H: 12.26%
C: 8.06%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.37%
H: 0.0%
C: 0.0%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -3.23%
H: 0.28%
C: -31.11%
urea fda approval therapeutics
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
RLFTF | $1.45 11.45% 2.2K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment fda drug set resubmission therapeutics review
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Published: 2022-06-21 (Crawled : 16:00) - biospace.com/
RLFTF | $1.45 11.45% 2.2K
|
n/a
|
| O: -21.33%
H: 27.12%
C: 14.41%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -15.91%
H: 8.65%
C: 8.65%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -10.23%
H: 0.0%
C: 0.0%
acer-001 fda drug application therapeutics review update
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.83%
H: 0.97%
C: -9.22%
fda expected trial therapeutics phase 3
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
Published: 2022-04-04 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 24.66%
H: 3.57%
C: -16.48%
fda granted therapy edsivo celiprolol grant designation
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle DisordersFDA sets PDUFA target action date of June 5, 2022
Published: 2021-10-06 (Crawled : 14:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 12.45%
H: 8.57%
C: 3.57%
urea new drug fda fda acceptance pdufa drug
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
Published: 2021-10-06 (Crawled : 13:00) - acertx.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 12.45%
H: 8.57%
C: 3.57%
urea new drug fda fda acceptance drug
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
Published: 2021-08-09 (Crawled : 13:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 2.83%
H: 4.33%
C: 3.54%
urea new drug treatment fda drug submission
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
Published: 2021-08-09 (Crawled : 07:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 2.83%
H: 4.33%
C: 3.54%
urea new drug treatment fda drug submission
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -0.33%
H: 2.62%
C: 0.0%
fda trial celiprolol edsivo
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
Published: 2021-05-25 (Crawled : 13:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.05%
H: 1.73%
C: -5.54%
fda submission
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle DisordersTopline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021
Published: 2020-12-22 (Crawled : 16:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.38%
H: 0.75%
C: -3.01%
fda trial results results urea trial fda ide enroll
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.